Impact of Tobacco, Marijuana, and Alcohol use on Overall Survival in Recurrent Metastatic head and neck Cancer Patients Treated with Immune Checkpoint Inhibitors

Author:

Alsavaf Mohammad Bilal1,Issa Majd1,Klamer Brett G2,Husain Marium1,Dibs Khaled1,Pan Xueliang2,Grecula John C1,Old Matthew O1,Konieczkowski David1,Mitchell Darrion L1,Baliga Sujith1,Carrau Ricardo L1,Rocco James W1,Bonomi Marcelo1,Blakaj Dukagjin M.1,Bhateja Priyanka1

Affiliation:

1. The Ohio State University Wexner Medical Center

2. The Ohio State University

Abstract

Abstract Background: The response rates to immune checkpoint inhibitors (ICI) remain low (13-20%) in metastatic head and neck cancer patients and better understanding of factors predictive of response to these agents is urgently needed. Here we explore the impact of smoking status, marijuana use and alcohol on treatment outcomes in recurrent-metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with ICI. Methods: We performed a retrospective analysis of 201 R/M HNSCC patients treated with ICI between January 15th 2016 and April 9th 2020 at a single institution. Results: Gender: 154 male (77%), 47 female (23%). Median age 61 (IQR: 55-68). ICI drug: pembrolizumab 100 (50%), nivolumab 91 (45%), nivolumab+ipilimumab 10 (5%). Line of therapy: first: 98 (49%), second and beyond: 103 (51%). Tumor site: oropharynx 84 (42%), oral cavity 45 (22%), larynx 26 (13%), other sites 46 (23%). p16 tumor status: negative 132 (66%), positive 69 (34%). Smoking status: former 111 (55%), never 54 (27%), current 36 (18%), median pack-year 18 (IQR: 0-37). Alcohol use: yes 110 (55%), no 91 (54%). Marijuana use: yes 47 (23%), no 154 (77%). Overall response rate: 36 (18%). Median OS: 12 months (95% CI: 9.4-14.8). Tobacco: former (HR: 0.75, 95% CI: 0.50, 1.11), current (HR: 0.58, 95% CI: 0.33, 1.02). Marijuana: yes (HR: 0.93, 95% CI: 0.58, 1.49). Alcohol: yes (HR: 1.04, 95% CI: 0.72, 1.49). Conclusion: In our cohort, smoking status, marijuana use and alcohol consumption did not have a statistically significant impact on OS in patients with R/M HNSCC treated with ICI. Trial registration: retrospectively registered.

Publisher

Research Square Platform LLC

Reference103 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. 2018 Nov;68(6):394–424. Available from: http://doi.wiley.com/10.3322/caac.21492

2. Kawakita D, Matsuo K. Alcohol and head and neck cancer. Cancer Metastasis Rev [Internet]. 2017 Sep 16;36(3):425–34. Available from: http://link.springer.com/10.1007/s10555-017-9690-0

3. Lambert R, Sauvaget C, de Camargo Cancela M, Sankaranarayanan R. Epidemiology of cancer from the oral cavity and oropharynx. Eur J Gastroenterol Hepatol [Internet]. 2011 Aug;23(8):633–41. Available from: http://journals.lww.com/00042737-201108000-00001

4. Head and Neck Cancer: Statistics | Cancer.Net [Internet]. Statistics adapted from the American Cancer Society’s publication, Cancer Facts & Figs, the National Cancer Institute website. 2022, and. 2022 [cited 2022 Sep 5]. Available from: https://www.cancer.net/cancer-types/head-and-neck-cancer/statistics

5. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Prim [Internet]. 2020 Nov 26;6(1):92. Available from: https://www.nature.com/articles/s41572-020-00224-3

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3